22 Oct 2022

NEW case study: Rhinovirus human challenge study

Find out how our team of experts at Virtus have helped to investigate the efficacy, safety and pharmacodynamics of a new inhaled immunomodulator.

Pulmotect wanted to generate a comprehensive dataset on the safety, pharmacodynamics and potential efficacy of PUL-042 to inform future trial design in COPD subjects, which was a potential target indication.

Discover how Virtus designed, conducted and analysed a human challenge study.

  • 100% successful infection rate
  • Demonstrated safety in target population
  • Over 30,000 unique data points generated
  • New biomarkers identified suggesting a unique mechanism of action

Got any questions? Email info@virtus-rr.com or call us on 0207 554 5855